Impact of Expression of Vimentin and Axl in Breast Cancer

Clinical Breast Cancer

Volumn 16, Issue 6, 2016, Pages 520-526.e2

  Tanaka, Kimihiro ^a   Tokunaga, Eriko ^a,b   Inoue, Yuka ^a   Yamashita, Nami ^a   Saeki, Hiroshi ^a   Okano, Shinji ^a   Kitao, Hiroyuki ^a   Oki, Eiji ^a   Oda, Yoshinao ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

Axl; Prognostic factor; Survival; Triple negative breast cancer; Vimentin

Indexed keywords

AXL PROTEIN; MESSENGER RNA; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; VIMENTIN; AXL RECEPTOR TYROSINE KINASE; ONCOPROTEIN; TUMOR MARKER;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BREAST CARCINOMA; CANCER PROGNOSIS; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHENOTYPE; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TRIPLE NEGATIVE BREAST CANCER; BREAST TUMOR; CANCER STAGING; CARCINOMA, DUCTAL, BREAST; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; JAPAN; MCF-7 CELL LINE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; JAPAN; MCF-7 CELLS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; TRIPLE NEGATIVE BREAST NEOPLASMS; VIMENTIN;

EID: 84995688273     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2016.06.015     Document Type: Article

References (28)

1. 1 Verma, A., Warner, S.L., Vankayalapati, H., et al. Targeting Axl and Mer kinases in cancer. Mol Cancer Ther 10 (2011), 1763–1773.
2. 2 Paccez, J.D., Vogelsang, M., Parker, M.I., et al. The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications. Int J Cancer 134 (2014), 1024–1033.
3. 3 Berclaz, G., Altermatt, H.J., Rohrbach, V., et al. Estrogen dependent expression of the receptor tyrosine kinase Axl in normal and malignant human breast. Ann Oncol 12 (2001), 819–824.
4. 4 Vuoriluoto, K., Haugen, H., Kiviluoto, S., et al. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene 30 (2011), 1436–1448.
5. 5 Gjerdrum, C., Tiron, C., Hoiby, T., et al. Axl is an essential epithelial-to-mesenchymal transition–induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A 107 (2010), 1124–1129.
6. 6 Liu, L., Greger, J., Shi, H., et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 69 (2009), 6871–6878.
7. 7 Elkabets, M., Pazarentzos, E., Juric, D., et al. AXL mediates resistance to PI3Kalpha inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. Cancer Cell 27 (2015), 533–546.
8. 8 O'Bryan, J.P., Frye, R.A., Cogswell, P.C., et al. axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 11 (1991), 5016–5031.
9. 9 Bose, R., Molina, H., Patterson, A.S., et al. Phosphoproteomic analysis of Her2/neu signaling and inhibition. Proc Natl Acad Sci U S A 103 (2006), 9773–9778.
10. 10 Hafizi, S., Dahlback, B., Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. Cytokine Growth Factor Rev 17 (2006), 295–304.
11. 11 Goruppi, S., Ruaro, E., Schneider, C., Gas6, the ligand of Axl tyrosine kinase receptor, has mitogenic and survival activities for serum starved NIH3T3 fibroblasts. Oncogene 12 (1996), 471–480.
12. 12 Goruppi, S., Ruaro, E., Varnum, B., et al. Requirement of phosphatidylinositol 3-kinase–dependent pathway and Src for Gas6-Axl mitogenic and survival activities in NIH 3T3 fibroblasts. Mol Cell Biol 17 (1997), 4442–4453.
13. 13 Goruppi, S., Yamane, H., Marcandalli, P., et al. The product of a gas6 splice variant allows the release of the domain responsible for Axl tyrosine kinase receptor activation. FEBS Lett 415 (1997), 59–63.
14. 14 Thiery, J.P., Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer 2 (2002), 442–454.
15. 15 Thiery, J.P., Acloque, H., Huang, R.Y., et al. Epithelial–mesenchymal transitions in development and disease. Cell 139 (2009), 871–890.
16. 16 Gupta, G.P., Massague, J., Cancer metastasis: building a framework. Cell 127 (2006), 679–695.
17. 17 Satelli, A., Li, S., Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci 68 (2011), 3033–3046.
18. 18 Yamashita, N., Tokunaga, E., Kitao, H., et al. Vimentin as a poor prognostic factor for triple-negative breast cancer. J Cancer Res Clin Oncol 139 (2013), 739–746.
19. 19 Tokunaga, E., Kimura, Y., Oki, E., et al. Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. Int J Cancer 118 (2006), 284–289.
20. 20 Wolff, A.C., Hammond, M.E., Schwartz, J.N., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131 (2007), 18–43.
21. 21 Cheang, M.C., Chia, S.K., Voduc, D., et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101 (2009), 736–750.
22. 22 Mackiewicz, M., Huppi, K., Pitt, J.J., et al. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res Treat 130 (2011), 663–679.
23. 23 Hong, C.C., Lay, J.D., Huang, J.S., et al. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett 268 (2008), 314–324.
24. 24 Gioia, R., Leroy, C., Drullion, C., et al. Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells. Blood 118 (2011), 2211–2221.
25. 25 Lay, J.D., Hong, C.C., Huang, J.S., et al. Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL. Cancer Res 67 (2007), 3878–3887.
26. 26 Mahadevan, D., Cooke, L., Riley, C., et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene 26 (2007), 3909–3919.
27. 27 Asiedu, M.K., Beauchamp-Perez, F.D., Ingle, J.N., et al. AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells. Oncogene 33 (2014), 1316–1324.
28. 28 Wilson, C., Ye, X., Pham, T., et al. AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs. Cancer Res 74 (2014), 5878–5890.